Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings Robert N. Weinreb, Jeffrey M. Liebmann, Keith R. Martin, Paul L. Kaufman,Jason L. Vittitow

January 1, 2018

View Press Release Corporate presentation Contact us
Previous